Psoriatic Arthritis for Anti-Rheumatic Drug Patients
A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease-modifying Anti-rheumatic Drugs
SEX AT BIRTH: All
LOCATION: University Hospitals Medical Centers
Learn More About This Research Study
For more information, please contact study coordinator, Amy Johnson, MD at 216-286-7369 or complete the form below.
The purpose of this study is to evaluate the efficacy and safety of deucravacitinib versus placebo in participants with active psoriatic arthritis who are naïve to biologic disease-modifying anti-rheumatic drugs. The long term extension period will provide additional long-term efficacy and safety information.
Who Can Participate
Participants diagnosed to have psoriatic arthritis (PsA) of at least 3 months duration at screening may be eligible for this study.